GlassScriptPhysician profile
Timothy J Widhalm
NPI 1437167038
$5,735.03
in general payments reported to CMS, 2019-2025
48 companies · $1,545 in 2025
The $1,545 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $351 · 2021: $539 · 2022: $133 · 2023: $1,386 · 2024: $1,298 · 2025: $1,545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,128 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,128.39 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $931.93 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Pfizer INC. | $545.06 | 2019-2025 | |
| Novo Nordisk INC | $499.29 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $417.06 | 2019-2025 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals LP | $398.64 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $350.98 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $317.47 | 2019-2024 | Spravato, Invega Sustenna |
| Bayer Healthcare Pharmaceuticals INC. | $187.31 | 2022-2025 | |
| Corcept Therapeutics | $165.33 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $161.69 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $156.16 | 2023 | Quviviq |
| Actelion Pharmaceuticals US, INC. | $152.34 | 2023-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.29 | 2020-2025 | |
| Glaxosmithkline, LLC. | $136.64 | 2019-2023 | Arexvy, Shingrix, Bexsero |
| Boston Scientific Corporation | $95.79 | 2019-2024 | Vercise, Watchman Access System |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Widhalm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.